-transparent.png){kind=logo}
14 patients with chronic bronchitis were subdivided into 2 groups of 7 patients. They were given at random 10 puffs of placebo or ipratropium bromide (0.2 mg). The mucociliary clearance rate was measured immediately after ipratropium inhalation (group 1) or 24 h after ipratropium inhalation (group 2). In group 1, the mucociliary clearance after ipratropium bromide was significantly better than after placebo (p less than 0.01). In group 2 there was no difference in the mucociliary clearance rates measured after ipratropium bromide or placebo, but the clearance rate still tended in favour of ipratropium bromide. We conclude that ipratropium bromide should be inhaled in high doses (0.2 mg) by hypersecretory patients with chronic bronchitis to improve mucociliary transport.
H Matthys, and
J Hundenborn, and
G Daikeler, and
D Köhler
October 1977,
Irish medical journal,
H Matthys, and
J Hundenborn, and
G Daikeler, and
D Köhler
January 1983,
Archivio Monaldi per la tisiologia e le malattie dell'apparato respiratorio,
H Matthys, and
J Hundenborn, and
G Daikeler, and
D Köhler
October 1980,
European journal of respiratory diseases,
H Matthys, and
J Hundenborn, and
G Daikeler, and
D Köhler
May 1994,
Chest,
H Matthys, and
J Hundenborn, and
G Daikeler, and
D Köhler
April 2003,
The Indian journal of medical research,
H Matthys, and
J Hundenborn, and
G Daikeler, and
D Köhler
August 1982,
Lancet (London, England),
H Matthys, and
J Hundenborn, and
G Daikeler, and
D Köhler
January 1989,
Respiration; international review of thoracic diseases,
H Matthys, and
J Hundenborn, and
G Daikeler, and
D Köhler
July 1977,
British journal of diseases of the chest,
H Matthys, and
J Hundenborn, and
G Daikeler, and
D Köhler
December 1981,
Chest,
H Matthys, and
J Hundenborn, and
G Daikeler, and
D Köhler
January 2003,
The Indian journal of chest diseases & allied sciences,
